复发、难治多发性骨髓瘤诊治进展:第19届欧洲血液学会年会报道

摘要

Relapsed/refractory multiple myeloma (MM) is always a challenge in the field of MM treatment.In the 19th European Hematology Association (EHA) annual congress,there was a detailed and full-length description on the definition,prognosis,therapeutic strategies and new drugs of the relapsed/refractory MM.New agents with activity and good tolerability are promising in the future.%复发、难治多发性骨髓瘤(MM)始终是MM治疗领域的一大难题.2014年第19届欧洲血液学会(EHA)年会围绕复发、难治MM,从定义、预后、治疗策略到新的药物进行了详细完整的阐述.兼顾有效性及安全性的新药在这一领域显示了良好的前景.